05-804
Anti-Tau (4-repeat isoform RD4) Antibody, clone 1E1/A6
culture supernatant, clone 1E1/A6, Upstate®
Synonym(s):
Anti-Tau antibody
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
mouse
Quality Level
antibody form
culture supernatant
antibody product type
primary antibodies
clone
1E1/A6, monoclonal
species reactivity
mouse, bovine, human, rat
manufacturer/tradename
Upstate®
technique(s)
immunohistochemistry: suitable
western blot: suitable
isotype
IgG
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... MAPT(4137)
mouse ... Mapt(17762) , Mapt(281296)
rat ... Mapt(29477)
Related Categories
General description
Microtubule Associated Proteins, or MAPS, bind to the tubulin subunits of microtubule structures and regulate their functional stability. In the cell MAPs bind to monomer and multimerized tubulin. MAP binding to multimerized tubulin further stabilizes the formation of higher order microtubulin structures. MAP binding to microtubule structures is mediated through phosporylation through Microtubule Affinity Regulated Kinase (MARK). Phosphorylation releases MAPs bound to microtubules, destabilizing the structure, driving it toward disassembly. There are predominately two MAP types, I, II. Type II MAP includes MAP2, MAP4, and tau and are found in nervous tissue. Six tau isoforms exist in brain tissue, and they are distinguished by their number of binding domains. Three isoforms have three binding domains and the other three have four binding domains. The binding domains are located in the carboxy-terminus of the protein and are positively-charged (allowing it to bind to the negatively-charged microtubule). The isoforms with four binding domains are better at stabilizing microtubules than those with three binding domains.
Specificity
Cross-reactivity with mouse and bovine expected due to sequence homology.
Recognizes Tau (4-repeat isoform RD4), Mr 45-65 kDa. Higher MW band (68-72 kDa) represents phosphorylated Tau.
Immunogen
Bovine thyroglobulin-conjugated synthetic peptide corresponding to amino acids 275-291 (VQIINKKLDLSNVQSKC) of human Tau (4-repeat isoform RD4). Region is flanking junction coded by adjacent exons 9 & 11 with the inclusion of exon 10. The immunizing sequence is identical in human, rat, mouse and bovine.
Application
Immunohistochemistry:
This antibody has been reported by an independent laboratory to detect Tau (4-repeat isoform RD4) in autoclaved paraffin brain sections. (De Silva, R., 2003;Togo, T., 2002)
Differential Detection of Tauopathies: (Togo, T., 2002)
This antibody has been reported by an independent laboratory to detect Tau (4-repeat isoform RD4) in autoclaved paraffin brain sections. (De Silva, R., 2003;Togo, T., 2002)
Differential Detection of Tauopathies: (Togo, T., 2002)
Research Category
Neuroscience
Neuroscience
Research Sub Category
Kinases & Phosphatases
Neurodegenerative Diseases
Kinases & Phosphatases
Neurodegenerative Diseases
This Anti-Tau (4-repeat isoform RD4) Antibody, clone 1E1/A6 is validated for use in IH, WB for the detection of Tau (4-repeat isoform RD4).
Quality
Routinely evaluated by western blot on rat brain cytosol fraction.
Western Blot Analysis:
A 1:1,000-1:10,000 dilution of this lot detected Tau (4-repeat isoform RD4) in a rat brain cytosolic fraction.
Western Blot Analysis:
A 1:1,000-1:10,000 dilution of this lot detected Tau (4-repeat isoform RD4) in a rat brain cytosolic fraction.
Target description
~68-72 kDa
Physical form
Mouse monoclonal cultured supernatant containing 0.05% sodium azide.
Frozen at -20°C.
Frozen at -20°C.
Unpurified
Storage and Stability
Stable for 1 year at -20°C from date of receipt.
Handling Recommendations: Upon first thaw, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance. Note: Variabillity in freezer temperatures below -20°C may cause glycerol containing solutions to become frozen during storage.
Handling Recommendations: Upon first thaw, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance. Note: Variabillity in freezer temperatures below -20°C may cause glycerol containing solutions to become frozen during storage.
Analysis Note
Control
Rat brain cytosolic fraction.
Rat brain cytosolic fraction.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
recommended
Product No.
Description
Pricing
Storage Class Code
10 - Combustible liquids
WGK
WGK 2
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies.
de Silva, R, et al.
Neuropathology and Applied Neurobiology, 29, 288-302 (2003)
The complex relationship between soluble and insoluble tau in tauopathies revealed by efficient dephosphorylation and specific antibodies
Hanger, D P, et al
Febs Letters, 531, 538-542 (2002)
Parenchymal and vascular lesions in ageing equine brains: histological and immunohistochemical studies.
M T Capucchio,M Marquez,P Pregel,L Foradada,M Bravo,G Mattutino,C Torre,D Schiffer et al.
Journal of Comparative Pathology null
Pamela McMillan et al.
The Journal of comparative neurology, 511(6), 788-803 (2008-10-18)
Tau is a microtubule-associated protein implicated in neurodegenerative tauopathies. Alternative splicing of the tau gene (MAPT) generates six tau isoforms, distinguishable by the exclusion or inclusion of a repeat region of exon 10, which are referred to as 3-repeat (3R)
The L266V tau mutation is associated with frontotemporal dementia and Pick-like 3R and 4R tauopathy.
Marion Hogg et al.
Acta neuropathologica, 106(4), 323-336 (2003-07-29)
We report a case of rapidly progressive frontotemporal dementia presenting at age 33 years. At autopsy there was severe atrophy of the frontal and temporal lobes. Tau-positive Pick bodies, which ultrastructurally were composed of straight filaments, were present, accompanied by
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service